Cargando…

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

ABSTRACT: Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salles, Gilles, Barrett, Martin, Foà, Robin, Maurer, Joerg, O’Brien, Susan, Valente, Nancy, Wenger, Michael, Maloney, David G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656728/ https://www.ncbi.nlm.nih.gov/pubmed/28983798 http://dx.doi.org/10.1007/s12325-017-0612-x

Ejemplares similares

Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study
por: Lanini, Simone, et al.
Publicado: (2013)

Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy
por: Al-Shammari, Ahmed Majeed, et al.
Publicado: (2016)

Meta-Analysis on Impact of Rituximab in Patients with Hematological Malignancies with Covid-19 Infection
por: Vegivinti, Charan Thej Reddy, et al.
Publicado: (2022)

Monitoring NK cell activity in patients with hematological malignancies
por: Viel, Sébastien, et al.
Publicado: (2013)

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab
por: Cattaneo, C., et al.
Publicado: (2021)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies
por: Jamois, Candice, et al.
Publicado: (2021)

The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience
por: Nissen, Johanna C, et al.
Publicado: (2014)

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
por: Davies, Andrew, et al.
Publicado: (2017)

Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021)

Hematologic Malignancies: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Two Cases of Cerebral Involvement in Malignant Lymphoma (CD20+) That Responded to Combination Therapy with Rituximab and Cladribine
por: Jo, Tatsuro, et al.
Publicado: (2012)

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
por: Song, Lina, et al.
Publicado: (2019)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
por: Robak, Pawel, et al.
Publicado: (2019)

Hematological patients profile admitted to an intensive care unit over 20 years experience
por: Fernandez Garda, R, et al.
Publicado: (2015)

Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment
por: Wang, Honglei, et al.
Publicado: (2020)

Clinical use of rituximab in haematological malignancies
por: Avivi, I, et al.
Publicado: (2003)

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
por: Bruno, Samantha, et al.
Publicado: (2022)

Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up
por: Hagström, Hannes, et al.
Publicado: (2018)

Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
por: Al-Kali, Aref, et al.
Publicado: (2010)

Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
por: Blumel, Susan, et al.
Publicado: (2014)

Vulvovaginal pyoderma gangrenosum in association with rituximab
por: Maloney, Catherine, et al.
Publicado: (2018)

Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies
por: Hayette, Sandrine, et al.
Publicado: (2021)

Carbamazepine and Hematological Malignancies
por: Yavaşoğlu, İrfan, et al.
Publicado: (2013)

Malignant benign hematology
por: Sholzberg, Michelle
Publicado: (2018)

Neoantigens in Hematologic Malignancies
por: Biernacki, Melinda A., et al.
Publicado: (2020)

Deubiquitinases in hematological malignancies
por: Lei, Hu, et al.
Publicado: (2021)

Autophagy in Hematological Malignancies
por: García Ruiz, Olga, et al.
Publicado: (2022)

Functional and quantitative evaluation of the 20S proteasome in serum and intracellular in145 moroccan patients with hematologic malignancies
por: Filali, Hassan, et al.
Publicado: (2022)

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2023)

Clonal Hematopoiesis: Role in Hematologic and Non-Hematologic Malignancies
por: Testa, Ugo, et al.
Publicado: (2022)

Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders
por: Găman, Amelia Maria
Publicado: (2023)

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008)

Human metapneumovirus pneumonia in patients with hematological malignancies
por: Godet, Cendrine, et al.
Publicado: (2014)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
por: Schieber, Timothy, et al.
Publicado: (2023)

Survival trends in hematological malignancies in the Nordic countries through 50 years
por: Hemminki, Kari, et al.
Publicado: (2022)

Outcomes in Patients with Hematological Malignancies Receiving Anti-CD20 Therapy in the Setting of COVID-19 Infection
por: Lopez, Carlos A, et al.
Publicado: (2020)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tr4ffrivpkcnq2o3hegprlp50v